AstraZeneca (LON:AZN) Earns “Outperform” Rating from Credit Suisse Group

Credit Suisse Group reaffirmed their outperform rating on shares of AstraZeneca (LON:AZN) in a report issued on Wednesday morning, ThisIsMoney.Co.Uk reports.

Other equities analysts have also issued reports about the company. Barclays raised their price target on AstraZeneca from GBX 9,200 ($113.22) to GBX 9,300 ($114.45) and gave the stock an overweight rating in a report on Wednesday. DZ Bank raised their price target on AstraZeneca from GBX 6,500 ($79.99) to GBX 7,300 ($89.84) and gave the stock a sell rating in a report on Friday, May 1st. Oddo Securities lowered AstraZeneca to a reduce rating and cut their price target for the stock from GBX 8,100 ($99.68) to GBX 7,600 ($93.53) in a report on Monday, June 22nd. Jefferies Financial Group reaffirmed a hold rating on shares of AstraZeneca in a report on Thursday, July 9th. Finally, Morgan Stanley reissued an equal weight rating and set a GBX 9,000 ($110.76) price objective on shares of AstraZeneca in a research note on Tuesday, July 21st. Six investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of GBX 8,347.78 ($102.73).

AstraZeneca stock opened at GBX 8,530 ($104.97) on Wednesday. AstraZeneca has a one year low of GBX 83.80 ($1.03) and a one year high of GBX 9,537.09 ($117.37). The business has a fifty day moving average price of GBX 8,583.32 and a 200-day moving average price of GBX 7,938.56. The company has a debt-to-equity ratio of 171.72, a current ratio of 0.75 and a quick ratio of 0.56. The firm has a market capitalization of $111.94 billion and a P/E ratio of 73.73.

The company also recently declared a dividend, which will be paid on Monday, September 14th. Shareholders of record on Thursday, August 13th will be given a dividend of GBX 69.60 ($0.86) per share. The ex-dividend date is Thursday, August 13th. This represents a yield of 0.8%. AstraZeneca’s payout ratio is 188.42%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: Hedge Funds Explained

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Latest News